Recent News (DJ)

AI in Pathology Market Size to Reach USD 1915.21Million by 2031, CAGR: 7.8% – Report by SNS Insider

EDBy
0


The global AI in pathology market is undergoing a transformative shift, poised for significant growth in the coming years. Traditionally, pathologists have relied on microscopes and their trained expertise to diagnose diseases by examining tissue samples. However, the integration of Artificial Intelligence (AI) is revolutionizing this field by offering unparalleled accuracy, efficiency, and objectivity in pathology workflows.

The AI in pathology market valuation will be reaching USD 1915.21 Million by 2031 and will grow at a CAGR of 7.8% over the forecast period of 2024-2031.

AI in Pathology Market
AI in Pathology Market

Download Free Sample Copy of AI in Pathology Market Report: https://www.snsinsider.com/sample-request/2844

Market Scope:

The market scope includes various components like AI-powered software solutions, digital pathology scanners that convert glass slides into digital images, and specific neural network architectures optimized for analysing these images. This technology finds application in diverse areas like cancer detection, personalized medicine, drug discovery, and streamlining routine diagnostic tasks.

List of AI in Pathology Companies Profiled in Report:

  • Roche
  • Leica Biosystems
  • Hamamatsu Photonics
  • Koninklijke Philips
  • 3D Hsitech
  • Apollo Enterprises Imaging
  • Xifin
  • Huron Digital Pathology
  • Visionpharm
  • Corista
  • Indica Labs
  • Objective Pathology Services

Opportunity analysis

The aging population, rising cancer incidences, and increasing healthcare expenditure globally are driving the demand for AI-powered pathology tools. Additionally, the growing adoption of digital pathology workflows creates a fertile ground for AI integration. Furthermore, AI’s ability to analyse vast amounts of data with unparalleled speed and accuracy offers immense potential for identifying subtle patterns and variations in tissue morphology, leading to earlier and more precise diagnoses.

Challenges:

The integration of AI into pathology holds immense promise, but faces hurdles before widespread adoption. A major challenge is the data requirement. Training AI models necessitates vast amounts of high-quality, annotated tissue samples. Fragmentation across healthcare systems and privacy regulations complicate data acquisition.  Furthermore, a lack of standardization in pathology practices, where image capture and diagnostic protocols vary, can hinder the generalizability of AI algorithms.  These factors contribute to a current market share of only around 2% for AI-powered pathology tools, according to industry estimates.  Despite these challenges, the potential benefits of AI in streamlining workflows, reducing errors, and aiding pathologists in a field experiencing burnout are undeniable. As the technology matures and data hurdles are addressed, we can expect AI’s role in pathology to grow significantly.

AI in Pathology Market Segmentation:

By Neural Network Type

  • Convolutional Neural Networks
  • Recurrent Neural Networks
  • Generative Adversarial Networks
  • MVPNet
  • Reinforced Auto Zoom Net

By Product Type

  • Scanners
  • Software
  • Communication Systems
  • Storage Systems

By Type

  • Human Pathology
  • Veterinary Pathology

By End User

  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Reference Laboratories
  • Academic and Research Institutes

By Application

  • Teleconsultation
  • Disease Diagnosis
  • Drug Discovery
  • Training and Education

Ask Your Query Before Buying this Research Report: https://www.snsinsider.com/enquiry/2844

Segmental Analysis:

The AI in pathology market provides to a diverse range of end users, each with distinct needs. Pharmaceutical & Biotechnology companies estimated 20% share in 2031 leverage AI for drug discovery, analysing vast datasets to identify potential treatments and optimize drug development. Hospitals & Reference Laboratories anticipated to hold the largest share at 35% by 2031 utilize AI for teleconsultation and improved diagnostics, enabling remote analysis and faster turnaround times. Academic & Research Institutes holds around 15% share in 2031 employ AI for training and education, developing new algorithms and supporting innovation in the field.

When it comes to applications, Disease Diagnosis is expected to hold the highest share of 25% by 2031 due to its crucial role in early detection and personalized medicine. Teleconsultation is also projected for significant growth, with AI facilitating remote consultations and improving access to pathology expertise for geographically dispersed patients

Regional Analysis:

North America currently dominates the market due to the strong presence of leading AI developers, high healthcare spending, and established digital pathology infrastructure. However, Asia Pacific is expected to witness the fastest growth rate fuelled by government initiatives promoting digital healthcare and a rapidly growing healthcare sector. Europe is another significant market with a supportive regulatory environment and a strong focus on personalized medicine.

Key Insights:

The impact of external factors like regulatory approvals and data privacy concerns cannot be ignored. Stringent regulations regarding AI-based medical devices can impede market growth. However, recent approvals by regulatory bodies like the FDA in the US for specific AI-powered pathology tools are encouraging signs. Data privacy is another crucial consideration, as AI algorithms rely on vast amounts of patient data. Robust data security protocols and adherence to ethical guidelines will be essential for building trust and ensuring widespread adoption.

Recent developments.

Leading companies like PaigeAI, InSignia Medical, and iPathology are continuously innovating and forging partnerships to develop and deploy cutting-edge AI solutions. For instance, PaigeAI partnered with Philips to integrate its AI algorithms into Philips’ digital pathology platform.

Buy AI in Pathology Market report: https://www.snsinsider.com/checkout/2844

Key Takeaways:

  • The AI in pathology market presents a significant growth opportunity driven by rising healthcare needs and the increasing adoption of digital pathology.
  • AI offers the potential for improved diagnostic accuracy, efficiency, and personalized medicine approaches.
  • Regional variations exist, with North America leading currently, but Asia Pacific poised for rapid growth.
  • Regulatory approvals, data privacy, and ongoing innovation by key players will significantly impact market development.
  • The integration of AI in pathology holds the promise of a future with more precise diagnoses, improved patient outcomes, and a transformed healthcare landscape.

For more information and a comprehensive analysis of the AI in Pathology market, please refer to the full report available at https://www.snsinsider.com/reports/ai-in-pathology-market-2844

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com/



Information contained on this page is provided by an independent third-party content provider. Binary News Network and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]

ED

Neuroprosthetics Market to Hit USD 30.26 billion by 2031, says SNS Insider

Previous article

Chicago Personal Injury Law Firm, Briskman Briskman & Greenberg, Releases Free eBook Exploring Pathways to Justice Following an Injury

Next article

You may also like

Comments

Comments are closed.

More in Recent News (DJ)

The 2025 Global Women’s Summit was held in Beijing, China on October 13. The summit, themed “Shared Destiny: Accelerating the New Process of Women’s Comprehensive Development”, was attended by more than 110 heads of state, government and parliamentary leaders, including Iceland’s President Thomas Dotille, Dominica’s President Burton, Ghana’s President Mahama, Mozambique’s Prime Minister Levi and Sri Lanka’s Prime Minister Amalasuria. The Chinese president Xi Jinping delivered a speech titled “Carrying Forward the Spirit of the Beijing World Conference on Women and Accelerating the New Process of Women’s Development” at the opening ceremony of the summit, noting that women are important creators, promoters and inheritors of human civilization, and promoting the development of women’s causes is the common responsibility of the international community. Over the past three decades, China has been fulfilling this commitment. The fourth United Nations World Conference on Women was held in Beijing, China in September 1995. The Beijing Declaration and Programme of Action were adopted at the conference. The Beijing Declaration, with “equality, development and peace” as its main thread, affirms the achievements of the international community in improving the status of women and clearly points out the equal rights that women should enjoy in all areas of society. The Programme of Action elaborates on the main problems faced by women in various countries and sets out specific strategic goals and action plans to address these difficulties, covering key areas such as education, health, economy and politics. Their birth has driven progress in the field of women worldwide. Three decades have passed, and China has made remarkable achievements in the field of women worldwide, step by step, in line with the spirit of the Beijing Declaration and Programme of Action. As the world’s largest developing country, China has made remarkable historic achievements by integrating women’s causes into the overall development of the country. In 2020, China won the largest battle against poverty in human history. As many as 690 million Chinese women moved into a moderately prosperous society in the same year, achieving the poverty reduction target of the United Nations 2030 Agenda for Sustainable Development ahead of schedule. In the field of health care, China’s maternal mortality rate has dropped from 61.9 per 100,000 in 1995 to 14.3 per 100,000 in 2024, a decrease of 76.9%, according to the white paper on China’s practices and achievements in promoting the all-round development of women in the new era released by The State Council. In the field of culture and education, female students accounted for 50.76 percent of higher education students in 2024, up 14.15 percent from 1995. Among them, female postgraduate students accounted for 50.01%, up 22.43 percent from 1995. At present, China is playing a significant role in the field of women’s rights worldwide. In 2015, China and UNESCO jointly established the Girls’ and Women’s Education Prize, which has so far helped more than 20 projects in 19 countries take root; From 2021 to 2023, China has collaborated with UNESCO to carry out the “African Girls’ Health Education Project” in Nigeria, Uganda and other countries, exploring suitable local education models. The Spring Bud Project, which originated from China’s native public welfare model, is a typical example of China’s cooperation with international girls’ education. The project, led by the All-China Women’s Federation and initiated by the China Children and Teenagers’ Fund in 1989, has successfully extended its multi-model of “assistance + companionship + empowerment” to Southeast Asian countries such as Cambodia. In Cambodia’s pilot program, the Spring Bud Project not only provided financial assistance but also introduced comprehensive services such as skills training, mental health counseling and girl protection. In 2023, the Spring Bud Project was awarded the UNESCO Prize for Girls’ and Women’s Education, highlighting the high recognition of the Chinese model by the international community. In addition, since 2018, China has implemented more than 100 training programs for women and children in developing countries, carried out academic degree programs in women’s leadership, and trained nearly 4,000 women in the field. In September 2025, China will host training courses for more than 40 female officials from developing countries such as Pakistan and the Central African Republic, sharing experience in grassroots governance. From the Beijing Declaration in 1995 to the Global Women’s Summit in 2025, China has fulfilled this 30-year commitment and is believed to continue to promote the development of women’s causes globally and take them to new heights in the future.

By ED0